30.22MMarket Cap-3284P/E (TTM)
5.9700High5.4100Low33.97KVolume5.4800Open5.5400Pre Close191.02KTurnover0.65%Turnover RatioLossP/E (Static)5.35MShares11.790052wk High1.26P/B29.34MFloat Cap2.310152wk Low--Dividend TTM5.19MShs Float1461.9999Historical High--Div YieldTTM10.11%Amplitude2.3100Historical Low5.6220Avg Price1Lot Size
Lipocine Stock Forum
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co(LLY.US)$ $Novo-Nordisk A/S(NVO.US)$ $Structure Therapeutics(GPCR.US)$ $Viking Therapeutics(VKTX.US)$ $Lipocine(LPCN.US)$
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Liquidia(LQDA.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$MorphoSys(MOR.US)$ Phase 3
$Immunocore(IMCR.US)$ Phase 3
$Crinetics(CRNX.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$Capricor Therapeutics(CAPR.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3 ...
NEWS
LIPOCINE ANNOUNCES LATE BREAKING ORAL PRESENTATION OF DATA FROM THE PHASE 2 STUDY OF LPCN 1148 AT EASL CONGRESS 2024
Lipocine Inc. announced that data from the Phase 2 study of LPCN 1148 will be presented at the EASL Congress 2024 in Italy. The study shows improvement in sarcopenia and hepatic encephalopathy in cirrhosis patients.
Positive
Data from the Phase 2 study of LPCN 1148 selected for late breaking oral presentation at EASL Congress 2024.
Intervention with oral L...
$CG Oncology(CGON.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Insmed(INSM.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phas...
In a recent surge of optimism for millions battling obesity and its related comorbidities, Lipocine Inc., a prominent biopharmaceutical company, has unveiled the promising results of their Phase 2 clinical trial for LPCN 2401. This innovative treatment has shown to significantly alter body compo...
NEWS
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Lipocine Inc. (NASDAQ: LPCN) announces positive results from a Phase 2 clinical trial for LPCN 2401, showing significant improvements in body composition. The treatment led to increased lean mass by 4.4% and decreased fat mass by 6.7%. Additionally, android fat decreased by 4.1% and bone mineral content increased by 2.8%. The treatment was well-tolerate...
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$Hutchmed (China)(HCM.US)$ Phase 3
$Viracta Therapeutics(VIRX.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Marinus Pharmaceuticals(MRNS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3 ...
No comment yet